First Berlin reiterates Buy on Pharming, cuts price target to EUR 2.4

• First Berlin reiterated a Buy on Pharming Group NV in its Q2 2026 results preview.
• Price target cut to EUR 2.40 from EUR 2.60, citing weaker-than-expected Q1 2026 Ruconest sales.
• Analyst Simon Scholes said investor concerns over share losses to Chiesi’s oral HAE drug Ekterly look overstated.
• Report attributed the Q1 Ruconest decline mainly to inventory drawdown, market exits, and a smaller competitive impact.
• First Berlin said 2026 guidance for Ruconest growth, accelerating Joenja growth, remains plausible.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pharming Group NV published the original content used to generate this news brief via EQS News (Ref. ID: rc_26270) on July 22, 2026, and is solely responsible for the information contained therein.